-
公开(公告)号：US20180244656A1
公开(公告)日：2018-08-30
申请号：US15737351
申请日：2016-06-24
发明人： Frank Bennett , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Xin Gu , Jack D. Scott , Haiqun Tang , Zhiqiang Zhao , Yuhua Huang , Dexi Yang , Katherine Young , Li Xiao , Zhibo Zhang , Jianmin Fu
IPC分类号： C07D403/10 , A61K31/4184 , C07D401/10 , A61K31/4709 , A61K31/416 , C07D413/10 , A61K31/423 , C07D417/10 , A61K31/428 , C07D417/14 , A61K31/496 , A61K31/5377 , A61K31/454 , C07D471/04 , C07D495/08 , C07D487/10 , A61K31/541 , C07D493/04 , C07D493/08 , C07D453/02 , C07D403/14 , C07D405/14 , A61K31/41 , A61K31/4245 , A61K31/4192 , A61K31/421 , A61K31/4196 , A61K31/198 , A61K31/431 , A61K31/546 , A61K31/4545 , A61K31/439 , A61K31/407 , A61P31/04
CPC分类号： C07D403/10 , A61K31/198 , A61K31/407 , A61K31/41 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/423 , A61K31/4245 , A61K31/428 , A61K31/431 , A61K31/437 , A61K31/4375 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/546 , A61K45/06 , A61P31/04 , C07D401/10 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/10 , C07D493/04 , C07D493/08 , C07D495/08
摘要： The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
-
公开(公告)号：US10544130B2
公开(公告)日：2020-01-28
申请号：US16244876
申请日：2019-01-10
发明人： Frank Bennett , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Xin Gu , Jack D. Scott , Haiqun Tang , Zhiqiang Zhao , Yuhua Huang , Dexi Yang , Katherine Young , Li Xiao , Zhibo Zhang , Jianmin Fu
IPC分类号： C07D403/10 , C07D403/12 , C07D413/14 , C07D401/10 , C07D403/14 , C07D407/14 , C07D413/10 , C07D417/10 , C07D417/14 , C07D471/04 , A61P31/04 , A61K31/416 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D487/04 , A61K31/198 , A61K31/407 , A61K31/41 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/431 , A61K31/439 , A61K31/496 , A61K31/541 , A61K31/546 , C07D405/14 , C07D453/02 , C07D487/10 , C07D493/04 , C07D493/08 , C07D495/08
摘要： The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
-
公开(公告)号：US20180179190A1
公开(公告)日：2018-06-28
申请号：US15737334
申请日：2016-06-24
发明人： Frank Bennett , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Xin Gu , Jack D. Scott , Haiqun Tang , Zhiqiang Zhao , Yuhua Huang , David Hunter , Dexi Yang , Katherine Young , Li Xiao , Zhibo Zhang , Jianmin Fu , Yunfeng Bai , Zhixiang Zheng , Xu Zhang
IPC分类号： C07D403/14 , A61K45/06 , A61K31/4184 , C07D401/14 , A61K31/454 , C07D471/04 , A61K31/437 , A61K31/4545 , C07D487/04 , A61K31/5025 , C07D403/10 , A61K31/416 , A61K31/4439 , C07D417/14 , A61K31/428 , A61K31/4375 , C07D413/14 , A61K31/423 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/506 , A61K31/498 , A61K31/5377 , A61P31/04
CPC分类号： C07D403/10 , A61K31/198 , A61K31/407 , A61K31/41 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/423 , A61K31/4245 , A61K31/428 , A61K31/431 , A61K31/437 , A61K31/4375 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/546 , A61K45/06 , A61P31/04 , C07D401/10 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/10 , C07D493/04 , C07D493/08 , C07D495/08
摘要： The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and RB are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
-
公开(公告)号：US09708336B2
公开(公告)日：2017-07-18
申请号：US15110431
申请日：2015-01-16
发明人： Mihir Mandal , Haifeng Tang , Li Xiao , Jing Su , Guoqing Li , Shu-Wei Yang , Weidong Pan , Haiqun Tang , Reynalda DeJesus , Jacqueline Hicks , Matthew Lombardo , Hong Chu , William Hagmann , Alex Pasternak , Xin Gu , Jinlong Jiang , Shuzhi Dong , Fa-Xiang Ding , Clare London , Dipshikha Biswas , Katherine Young , David N. Hunter , Zhiqiang Zhao , Dexi Yang
IPC分类号： C07D491/048 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K45/06 , C07D401/04 , C07D409/10 , C07D487/04 , C07D471/10 , C07D471/04 , C07D451/04 , C07D417/14 , C07D417/10 , C07D413/10 , C07D401/14 , C07D405/12 , C07D405/10 , C07D403/10 , C07D401/10 , C07D413/14 , C07D405/14 , A61K31/41 , C07D257/04 , A61K31/197 , A61K31/407 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427
CPC分类号： C07D491/048 , A61K31/197 , A61K31/407 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K45/06 , C07D257/04 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/10 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D451/04 , C07D471/04 , C07D471/10 , C07D487/04 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
-
公开(公告)号：US20200281913A1
公开(公告)日：2020-09-10
申请号：US16631673
申请日：2018-07-12
发明人： Alexander Pasternak , Shuzhi Dong , Jack D. Scott , Haiqun Tang , Zhiqiang Zhao , Dexi Yang , Xin Gu , Jinlong Jiang , Li Xiao
IPC分类号： A61K31/454 , C07D401/10 , C07D401/14 , C07D413/10 , C07D498/10 , C07D471/10 , C07D403/10 , C07D403/14 , C07D471/08 , C07D405/14 , A61K31/41 , A61K31/5377 , A61K31/5386 , A61K31/438 , A61K31/55 , A61K31/496 , A61K31/439 , A61K31/551 , A61K31/407 , A61K31/198 , A61P31/04
摘要： The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
-
公开(公告)号：US20190144432A1
公开(公告)日：2019-05-16
申请号：US16244876
申请日：2019-01-10
发明人： Frank Bennett , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Xin Gu , Jack D. Scott , Haiqun Tang , Zhiqiang Zhao , Yuhua Huang , Dexi Yang , Katherine Young , Li Xiao , Zhibo Zhang , Jianmin Fu
IPC分类号： C07D403/10 , A61K31/198 , C07D403/12 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/431 , A61K31/439 , A61K31/496 , A61K31/541 , A61K31/546 , C07D405/14 , C07D453/02 , C07D487/10 , C07D493/04 , C07D493/08 , C07D495/08 , A61K31/407 , A61K31/5025 , A61K31/517 , A61K31/5377 , A61K45/06 , C07D401/14 , A61P31/04 , A61K31/416 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/498 , C07D487/04 , A61K31/506 , C07D471/04 , C07D417/14 , C07D417/10 , C07D413/10 , C07D407/14 , C07D403/14 , C07D401/10 , C07D413/14 , A61K31/41
CPC分类号： C07D403/10 , A61K31/198 , A61K31/407 , A61K31/41 , A61K31/416 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/423 , A61K31/4245 , A61K31/428 , A61K31/431 , A61K31/437 , A61K31/4375 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K31/546 , A61K45/06 , A61P31/04 , C07D401/10 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/10 , C07D493/04 , C07D493/08 , C07D495/08
摘要： The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
-
公开(公告)号：US10221163B2
公开(公告)日：2019-03-05
申请号：US15737351
申请日：2016-06-24
发明人： Frank Bennett , Jinlong Jiang , Alexander Pasternak , Shuzhi Dong , Xin Gu , Jack D. Scott , Haiqun Tang , Zhiqiang Zhao , Yuhua Huang , Dexi Yang , Katherine Young , Li Xiao , Zhibo Zhang , Jianmin Fu
IPC分类号： C07D403/14 , C07D403/10 , C07D403/12 , C07D413/14 , C07D401/10 , C07D407/14 , C07D413/10 , C07D417/10 , C07D417/14 , C07D471/04 , A61P31/04 , A61K31/416 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D487/04 , A61K31/198 , A61K31/407 , A61K31/41 , A61K31/4192 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/431 , A61K31/439 , A61K31/496 , A61K31/541 , A61K31/546 , C07D405/14 , C07D453/02 , C07D487/10 , C07D493/04 , C07D493/08 , C07D495/08
摘要： The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
-
公开(公告)号：US09839642B2
公开(公告)日：2017-12-12
申请号：US15309533
申请日：2015-05-04
发明人： Haifeng Tang , Shu-Wei Yang , Mihir Mandal , Jing Su , Guoqing Li , Weidong Pan , Haiqun Tang , Reynalda DeJesus , Jianping Pan , William Hagmann , Fa-Xiang Ding , Li Xiao , Alexander Pasternak , Yuhua Huang , Shuzhi Dong , Dexi Yang
IPC分类号： A61K31/407 , A61K31/41 , A61K31/427 , A61K31/43 , A61K31/44 , A61K31/496 , A61K31/546
CPC分类号： A61K31/546 , A61K31/407 , A61K31/41 , A61K31/427 , A61K31/43 , A61K31/44 , A61K31/496 , A61K45/06 , A61K2121/00 , C07D257/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/10 , C07D409/06 , C07D413/06 , C07D413/14 , C07D417/06 , C07D471/04 , C07D471/10 , C07D487/04 , A61K2300/00
摘要： The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
-
公开(公告)号：US20230018413A1
公开(公告)日：2023-01-19
申请号：US17632065
申请日：2020-08-03
发明人： Stephane L. Bogen , Ping Chen , Dane James Clausen , Jinsong Hao , Dipannita Kalyani , Michael T. Rudd , Shawn P. Walsh , Lan Wei , Dexi Yang
IPC分类号： C07D403/04 , C07D207/14 , C07D401/04 , C07D471/04 , C07D417/04 , C07D413/10 , C07D417/14 , C07D413/04 , C07D409/04 , C07D405/04 , C07D498/04 , C07D491/048
摘要： The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
-
公开(公告)号：US20220144771A1
公开(公告)日：2022-05-12
申请号：US17430409
申请日：2020-02-11
发明人： Stephane L. Bogen , Michael J. Breslin , Dane James Clausen , Anthony Ginnetti , Michael T. Rudd , Shawn J. Stachel , Craig A. Stump , Dexi Yang
IPC分类号： C07D207/14
摘要： The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.047 秒)
